26 citations,
October 2017 in “Clinical Reviews in Allergy & Immunology” Autoimmune liver diseases are likely linked to certain skin conditions like vitiligo and psoriasis.
26 citations,
February 2002 in “Urologic clinics of North America” The document concludes that it's important to understand the placebo effect when evaluating the effectiveness of treatments in medical trials.
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
25 citations,
July 2021 in “Journal of Medical Virology” COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.
25 citations,
May 2020 in “Aesthetic Surgery Journal” The regenerative solution, tSVF, is a safe and effective treatment for various conditions like aged skin, scars, wounds, and more, but more research is needed to find the best way to use it.
25 citations,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
25 citations,
October 2018 in “Journal of The American Academy of Dermatology” Erosive pustular dermatosis of the scalp is a type of skin inflammation often confused with other conditions, requiring continuous treatment.
25 citations,
December 2017 in “Facial Plastic Surgery” Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.
25 citations,
May 2016 in “Progress in Biophysics & Molecular Biology” R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.
25 citations,
October 2015 in “Dermatology” Dapsone improved pustular psoriasis in patients who didn't respond to other treatments and is considered a well-tolerated option.